MY175269A - Single high dose of mva induces a protective immune response in neonates and infants - Google Patents
Single high dose of mva induces a protective immune response in neonates and infantsInfo
- Publication number
- MY175269A MY175269A MYPI2015703045A MYPI2015703045A MY175269A MY 175269 A MY175269 A MY 175269A MY PI2015703045 A MYPI2015703045 A MY PI2015703045A MY PI2015703045 A MYPI2015703045 A MY PI2015703045A MY 175269 A MY175269 A MY 175269A
- Authority
- MY
- Malaysia
- Prior art keywords
- immune response
- high dose
- single high
- protective immune
- neonates
- Prior art date
Links
- 230000001681 protective effect Effects 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788722P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY175269A true MY175269A (en) | 2020-06-17 |
Family
ID=50389388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015703045A MY175269A (en) | 2013-03-15 | 2014-03-14 | Single high dose of mva induces a protective immune response in neonates and infants |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707291B2 (enExample) |
| EP (2) | EP2968524A1 (enExample) |
| JP (1) | JP6480875B2 (enExample) |
| KR (1) | KR102269491B1 (enExample) |
| CN (1) | CN105101993A (enExample) |
| AU (4) | AU2014231229A1 (enExample) |
| BR (1) | BR112015021781A2 (enExample) |
| CA (1) | CA2905569C (enExample) |
| EA (1) | EA034825B1 (enExample) |
| HK (1) | HK1216860A1 (enExample) |
| IL (1) | IL241059B (enExample) |
| MX (1) | MX376293B (enExample) |
| MY (1) | MY175269A (enExample) |
| SG (2) | SG10201707340XA (enExample) |
| UA (1) | UA126785C2 (enExample) |
| WO (1) | WO2014139687A1 (enExample) |
| ZA (1) | ZA201507017B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034825B1 (ru) * | 2013-03-15 | 2020-03-25 | Бавариан Нордик А/С | Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев |
| WO2015136056A1 (en) | 2014-03-12 | 2015-09-17 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus |
| US20230233670A1 (en) * | 2020-06-10 | 2023-07-27 | Bavarian Nordic A/S | A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9117596D0 (en) * | 1991-08-15 | 1991-10-02 | John Gibson Lifting Gear Ltd | Pulling system |
| US5471902A (en) * | 1994-02-22 | 1995-12-05 | Athenry Enterprises Limited | Tuning system for pianos |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1420822B2 (en) | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| CN101128217B (zh) * | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| CA2662730A1 (en) * | 2006-09-08 | 2008-03-13 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| JP2013507107A (ja) * | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| US9463238B2 (en) * | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| US10111946B2 (en) * | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| SI2879702T1 (sl) * | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| EA034825B1 (ru) * | 2013-03-15 | 2020-03-25 | Бавариан Нордик А/С | Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев |
-
2014
- 2014-03-14 EA EA201591803A patent/EA034825B1/ru not_active IP Right Cessation
- 2014-03-14 UA UAA201509740A patent/UA126785C2/uk unknown
- 2014-03-14 WO PCT/EP2014/000693 patent/WO2014139687A1/en not_active Ceased
- 2014-03-14 KR KR1020157029515A patent/KR102269491B1/ko active Active
- 2014-03-14 JP JP2015561981A patent/JP6480875B2/ja active Active
- 2014-03-14 EP EP14713036.3A patent/EP2968524A1/en not_active Ceased
- 2014-03-14 SG SG10201707340XA patent/SG10201707340XA/en unknown
- 2014-03-14 CN CN201480015857.9A patent/CN105101993A/zh active Pending
- 2014-03-14 HK HK16104937.0A patent/HK1216860A1/zh unknown
- 2014-03-14 BR BR112015021781A patent/BR112015021781A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015011388A patent/MX376293B/es active IP Right Grant
- 2014-03-14 MY MYPI2015703045A patent/MY175269A/en unknown
- 2014-03-14 EP EP20163606.5A patent/EP3708187A1/en active Pending
- 2014-03-14 SG SG11201507192SA patent/SG11201507192SA/en unknown
- 2014-03-14 CA CA2905569A patent/CA2905569C/en active Active
- 2014-03-14 US US14/776,881 patent/US9707291B2/en active Active
- 2014-03-14 AU AU2014231229A patent/AU2014231229A1/en not_active Abandoned
-
2015
- 2015-09-02 IL IL241059A patent/IL241059B/en active IP Right Grant
- 2015-09-21 ZA ZA2015/07017A patent/ZA201507017B/en unknown
-
2019
- 2019-02-12 AU AU2019200977A patent/AU2019200977A1/en not_active Abandoned
-
2020
- 2020-10-29 AU AU2020260472A patent/AU2020260472A1/en not_active Abandoned
-
2022
- 2022-09-20 AU AU2022235527A patent/AU2022235527B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015011388A (es) | 2016-02-03 |
| EP3708187A1 (en) | 2020-09-16 |
| JP6480875B2 (ja) | 2019-03-13 |
| NZ711569A (en) | 2021-03-26 |
| AU2020260472A1 (en) | 2020-11-26 |
| IL241059A0 (en) | 2015-11-30 |
| ZA201507017B (en) | 2018-12-19 |
| IL241059B (en) | 2020-10-29 |
| JP2016514114A (ja) | 2016-05-19 |
| BR112015021781A2 (pt) | 2017-07-18 |
| HK1216860A1 (zh) | 2016-12-09 |
| SG11201507192SA (en) | 2015-10-29 |
| US9707291B2 (en) | 2017-07-18 |
| AU2019200977A1 (en) | 2019-02-28 |
| EA201591803A1 (ru) | 2016-02-29 |
| UA126785C2 (uk) | 2023-02-08 |
| AU2014231229A1 (en) | 2015-09-17 |
| AU2022235527B2 (en) | 2023-10-26 |
| CN105101993A (zh) | 2015-11-25 |
| CA2905569A1 (en) | 2014-09-18 |
| KR20150129027A (ko) | 2015-11-18 |
| SG10201707340XA (en) | 2017-10-30 |
| KR102269491B1 (ko) | 2021-06-25 |
| US20160030551A1 (en) | 2016-02-04 |
| EP2968524A1 (en) | 2016-01-20 |
| EA034825B1 (ru) | 2020-03-25 |
| AU2022235527A1 (en) | 2022-10-13 |
| WO2014139687A1 (en) | 2014-09-18 |
| CA2905569C (en) | 2023-07-25 |
| MX376293B (es) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY196432A (en) | Methods Of Using Human Milk Oligosaccharides For Improving Airway Respiratory Health | |
| PH12016500773A1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section | |
| BR112015027281A2 (pt) | combinações de dosagens para reduzir respostas imunológicas humorais indesejadas | |
| PH12019502501A1 (en) | Preterm infant formula containing butyrate and uses thereof | |
| PH12016501974A1 (en) | Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides | |
| MX2016006817A (es) | Composicion liquida fortificante de leche con un contenido de lipidos relativamente alto. | |
| TN2015000403A1 (en) | Methods for treating psoriasis using an anti-il-23 antibody | |
| PH12012501704B1 (en) | Nutritional compositions | |
| TN2016000435A1 (en) | Novel macrocyclic compounds. | |
| MX379201B (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX378607B (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
| WO2014179771A8 (en) | Dosing combinations for reducing undesired humoral immune responses | |
| PH12018500953A1 (en) | Nutritional compositions and infant formulas to promote myelination in the brain | |
| MX2015012548A (es) | Metodos para estimular la maduracion de pulmones e intestinos infantiles. | |
| HK1216860A1 (zh) | 单次高剂量的mva在新生儿和婴儿中诱导保护性免疫反应 | |
| PH12018500924A1 (en) | Nutritional compositions and infant formulas to promote myelination in the brain | |
| MX2015014309A (es) | Modulador de sabor y metodo para utilizar el mismo. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| PH12017501953A1 (en) | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children | |
| MX2018006296A (es) | Composiciones nutritivas y formulas infantiles para promover la mielinizacion en el cerebro. | |
| MX2018006290A (es) | Composiciones nutritivas y formulas infantiles para promover la mielinizacion en el cerebro. | |
| PH12017500466A1 (en) | Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children | |
| PH12014502030A1 (en) | Lactoferrin for preventing or treating diarrhea | |
| Alangari | Interferon-γ |